Sanofi
Sanofi (SNY): 529 pipeline candidates · 59 upcoming catalysts · ~2 mo cash runway · 512 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
1.7 months
0% dilution
Lead: Phase 3
529 candidates
59 upcoming, next in ~74d
N/A
A transparent, data-derived signal for Sanofiacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$105.9B
Cash
$877.0M
Quarterly Burn
$17.4B
Runway
1.7 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (529 candidates)
| Drug | Phase |
|---|---|
| 150mg vandetanib | Phase 4 |
| 20vpcv | Phase 3 |
| 20vpcv | Phase 3 |
| 20vpcv licensed vaccine | Phase 3 |
| 20vpcv licensed vaccine | Phase 3 |
| 300mg vandetanib | Phase 4 |
| acne mrna vaccine | Phase 1/Phase 2 |
| acne mrna vaccine | Phase 3 |
| activated charcoal | Phase 3 |
| adg126 | Phase 1/Phase 2 |
Showing 10 of 529 candidates. Sign up for full pipeline.
Upcoming Catalysts (59)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
737
Total value held
$8.88B
| Holder | Shares | Value |
|---|---|---|
| dodge & cox | 29,504,632 | $1.42B |
| morgan stanley | 12,511,867 | $602.8M |
| bank of america corp /de/ | 9,484,350 | $457.0M |
| franklin resources inc | 7,165,193 | $345.2M |
| barrow hanley mewhinney & strauss llc | 5,887,466 | $283.7M |
| mondrian investment partners ltd | 5,040,065 | $242.8M |
| federated hermes, inc. | 4,754,359 | $229.1M |
| fmr llc | 4,010,161 | $193.2M |
| envestnet asset management inc | 3,861,894 | $186.1M |
| raymond james financial inc | 3,812,745 | $183.7M |
Showing top 10 of 737 institutional holders of Sanofi. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Sanofi's pipeline?
Sanofi (SNY) has 529 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sanofi's lead drug candidate?
Sanofi's most advanced tracked candidate is 150mg vandetanib (Phase 4) for Thyroid Cancer.
What is Sanofi's next catalyst?
Sanofi's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Eff" — expected August 31, 2026.
What is Sanofi's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sanofi has approximately 1.7 months of cash runway.
What is Sanofi's market capitalization?
Sanofi's market capitalization is approximately $105.9B.
Get the full picture on Sanofi
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.